Tumour-derived exosomes and their role in cancer-associated T-cell signalling defects

British Journal of Cancer

Volumn 92, Issue 2, 2005, Pages 305-311

  Taylor, D D ^a   Gercel Taylor C ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

Activation signaling; Exosomes; Membrane vesicles; Ovarian cancer; T lymphocytes

Indexed keywords

ALKALINE PHOSPHATASE PLACENTA ISOENZYME; CD3 ANTIGEN; DNA FRAGMENT; FAS ANTIBODY; FAS LIGAND; HLA A ANTIGEN; JANUS KINASE 3; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MEMBRANE PROTEIN; NUCLEOPHOSMIN; TUMOR ANTIGEN; TUMOR SUSCEPTIBILITY GENE 101 PROTEIN;

ADULT; APOPTOSIS; ARTICLE; ASCITES; CELL CULTURE; CONTROLLED STUDY; ELECTROPHORESIS; EXOSOME; FEMALE; HUMAN; HUMAN CELL; MEMBRANE VESICLE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR CELL; WESTERN BLOTTING;

ANTIGENS, CD3; ANTIGENS, NEOPLASM; BLOTTING, WESTERN; CELL MEMBRANE; CELLS, CULTURED; CYTOPLASMIC VESICLES; DNA FRAGMENTATION; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; JANUS KINASE 3; LYMPHOCYTE ACTIVATION; OVARIAN NEOPLASMS; PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

EID: 14844334129     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6602316     Document Type: Article

References (44)

1. André F, Schartz NE, Chaput N, Flament C, Raposo G, Amogorena S, Angevin E, Zitvogel L (2002a) Tumour-derived exosomes: a new source of tumour rejection antigens. Vaccine 20: A28-A31
2. André F, Schartz NEC, Movassagh M, Flament C, Pautier P, Morice P, Pomel C, Lhomme C, Escudier B, LeChevalier T, Tursz T, Amigorena S, Raposo G, Angevin E, Zitvogel L (2002b) Malignant effusions and immunogenic tumour-derived exosomes. Lancet 360: 295-305
3. Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B, Kaye SB (1993) Increased accumulation of p53 protein in cisplatin-resistant ovarian cell lines. Int J Cancer 55: 678-684
4. Chaput N, Schartz NE, André F, Zitvogel L (2003) Exosomes for immunotherapy of cancer. Adv Exp Med Biol 532: 215-221
5. Chaput N, Taieb J, Schartz NEC, Andre F, Angevin E, Zitvogel L (2004) Exosome-based immuno-therapy. Cancer Immunol Immunother 53: 234-239
6. Denzer K, Kleijmeer MJ, Heijnen HFG, Stoorvogel W, Geuze HJ (2000) Exosome: from internal vesicle of the multivesicular body to intercellular signaling device. J Cell Sci 113: 3365-3374
7. Gerçel-Taylor C, Bazzett LB, Taylor DD (2001) Presence of aberrant tumour-reactive immunoglobulins in the circulation of patients with gynecologic malignancies. Gynecol Oncol 81: 71-76
8. Gerçel-Taylor C, O'Connor SM, Lam GK, Taylor DD (2002) Shed membrane fragment modulation of CD3-ξ during pregnancy, link with induction of apoptosis. J Reprod Immunol 56: 29-44
9. Gibb RK, Taylor DD, Wan T, O'Connor DM, Doering DL, Gerçel-Taylor C (1997) Apoptosis as a measure of cheomsensitivity to cisplatin and taxol therapy in ovarian cancer cell lines. Gynecol Oncol 65: 13-22
10. Goldsmith JD, Pawel B, Goldblum JR, Pasha TL, Roberts S, Nelson P, Khurana JS, Frederic G, Zhang PJ (2002) Detection and diagnostic utilization of placental alkaline phosphatase in muscular tissue and tumours with myogenic differentiation. Am J Surg Pathol 26: 1627-1633
11. Graves LE, Ariztia EV, Navari JR, Matzel HJ, Stack MS, Fishman DA (2004) Preinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res 64: 7045-7049
12. Green DR, Droin N, Pinkoski M (2003) Activation-induced cell death in T cells. Immunol Rev 193: 70-81
13. Heijnen HFG, Schiel AE, Fijnheer R, Geuze HJ, Sixma JJ (1999) Activated platelets release two types of membrane vesicles: microvesicles by surface shedding and exosomes derived from exocytosis of multivesicular bodies and alpha granules. Blood 94: 3791-3799
14. Johnstone RM, Adam M, Hammond JR, Orr L, Turbide C (1987) Vesicle formation during reticulocyte maturation. Association of plasma membrane activates with released vesicles (exosomes). J Biol Chem 262: 9412-9420
15. Katsanis WA, Shields LBE, Spinnato JA, Gerçel-Taylor C, Taylor DD (1998) Immune recognition of endometrial tumour antigens induced by multiparity. Gynecol Oncol 70: 33-39
16. Kim JV, Latouche JB, Riviére I, Sadelain M (2004) The ABCs of artificial antigen presentation. Nat Biotechnol 22: 403-410
17. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacterio-phage T4. Nature 227: 680-685
18. Martinez-Lorenzo MJ, Anel A, Gamen S, Monle NI, Lasierra P, Larrad L, Pineiro A, Alava MA, Naval J (1999) Activated human T cells release bioactive Fas ligand and APO2 ligand in microvesicles. J. Immunol 163: 1274-1281
19. Pan BT, Teng K, Wu C, Adam M, Johnstone RM (1985) Electron microscopic evidence for externalization of the transferring receptor in vesicular form in sheep reticulocytes. J Cell Biol 101: 942-948
20. Pelton JJ, Taylor DD, Fowler WC, Taylor CG, Carp NZ, Weese JL (1991) Lymphokine activated killer (LAK) cell suppressor factor in malignant effusions. Arch Surg 126: 476-480
21. Poutsiaka DD, Schroder EW, Taylor DD, Levy EM, Black PH (1985a) Shed membrane vesicles from murine melanoma cells selectively inhibit the expression of Ia antigens by macrophages. J Immunol 134: 138-144
22. Poutsiaka DD, Taylor DD, Levy EM, Black PH (1985b) Inhibition of recombinant interferon-gamma induced Ia antigen expression. J Immunol 134: 145-150
23. Rabinowich H, Reichert TE, Kashii Y, Gastman BR, Bell MC, Whiteside TL (1998) Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells: implications for altered expression of T cell receptor in tumour associated lymphocytes. J Clin Invest 101: 2579-2588
24. Raposo G, Nijman HW, Stoorvogel W, Liejendekker R, Harding CV, Melief CJ, Geuze HJ (1996) B lymphocytes secrete antigen-presenting vesicles. J Exp Med 183: 1161-1172
25. Raposo G, Tenza D, Mecheri S, Peronet R, Bonnerot C, Desaymard C (1997) Accumulation of major histocompatibility complex class II molecules in mast cell secretory granules and their release upon degranulation. Mol Biol Cell 8: 2631-2645
26. Shigenari A, Ando A, Baba T, Yamamoto T, Katsuoka Y, Inoko H (1998) Characterization of alkaline phosphatase genes expressed in seminoma by cDNA cloning. Cancer Res 58: 5079-5082
27. Stoorvogel W, Kleijmeer MJ, Geuze HJ, Raposo G (2002) The biogenesis and functions of exosomes. Traffic 3: 321-330
28. Taylor DD, Black PH (1985) Inhibition of macrophage Ia antigen expression by shed plasma membrane vesicles from metastatic murine melanoma lines. J Natl Cancer Inst 74: 859-867
29. Taylor DD, Black PH (1986) Shedding of plasma membrane fragments: neoplastic and developmental importance. In Developmental Biology, Vol. 3, Steinberg MS (ed) pp 33-57. New York: Plenum Press
30. Taylor DD, Black PH (1987) Neoplastic and developmental importance of plasma membrane vesicles. Amer Zool 26: 411-415
31. Taylor DD, Chou IN, Black PH (1983a) Isolation of plasma membrane fragments from cultured murine melanoma cells. Biochem Biophys Res Comm 113: 470-476
32. Taylor DD, Doellgast GJ (1979) Quantitation of peroxidase-antibody binding to membrane fragments using column chromatography. Anal Biochem 98: 53-59
33. Taylor DD, Gerçel-Taylor C, Gall SA (1996) Expression and shedding of CD44 isoforms by gynecologic cancer patients. J Soc Gynecol Invest 3: 289-294
34. Taylor DD, Gerçel-Taylor C, Jiang CG, Black PH (1988) Characterization of plasma membrane shedding from murine melanoma cells. Int J Cancer 41: 629-635
35. Taylor DD, Gerçel-Taylor C, Lyons KS, Stanson J, Whiteside TL (2003) Suppression of TcR/CD3-ξ by shed membrane vesicles from ovarian tumours. Clin Cancer Res 9: 5113-5119
36. Taylor DD, Gerçel-Taylor C, Weese JL (1989) Expression and shedding of mdr-1 antigen by variants of the murine B16 melanoma. Surg Forum 40: 406-408
37. Taylor DD, Homesley HD, Doellgast GJ (1980) Binding of specific peroxidase-labeled antibody to placental-type alkaline phosphatase on tumour-derived membrane fragments. Cancer Res 40: 4064-4069
38. Taylor DD, Homesley HD, Doellgast GJ (1984) Identification of components responsible for the autologous humoral responses of ovarian cancer patients. Am J Reprod Immunol 6: 179-184
39. Taylor DD, Homesley HD, Doellgast GJ (1983b) Membrane-associated immunoglobulins in cyst and ascites fluids of ovarian cancer patients. Am J Reprod Immunol 3: 7-11
40. Taylor DD, Lyons KS, Gerçel-Taylor C (2002) Shed membrane fragment-associated markers for endometrial and ovarian cancers. Gynecol Oncol 84: 443-448
41. Théry C, Regnault A, Garin J, Wolfers J, Zitvogel L, Ricciardi-Castagnoli P, Raposo G, Amigorena S (1999) Molecular characterization of dendritic cell-derived exosomes. Selective accumulation of the heat shock protein hsc73. J Cell Biol 147: 599-610
42. Théry C, Zitvogel L, Amigorena S (2002) Exosomes: composition, biogenesis, and function. Nat Rev Immunol 2: 569-579
43. Whiteside TL (2002) Tumour-induced death of immune cells: Its mechanisms and consequences. Sem Cancer Biol 12: 43-50
44. Wolfers J, Lozier A, Raposo G, Regnault A, Théry C, Masurier C, Flament C, Pouzieux S, Faure F, Tursz T, Angevin E, Amogorena S, Zitvogel L (2001) Tumour-derived exosomes are a source of shared tumour rejection antigens for CTL cross-priming. Nat Med 7: 297-303